About InFlectis BioScience
InFlectis BioScience is a company based in Nantes (France) founded in 2013 by Philippe GuEdat and Pierre Miniou. InFlectis BioScience has raised $8.76 million across 2 funding rounds from investors including GO CAPITAL, Remiges Ventures and Crédit Mutuel Equity. InFlectis BioScience offers products and services including Small Molecule Therapeutics. InFlectis BioScience operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Nantes, France
- Founders Philippe GuEdat, Pierre Miniou
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.76 M (USD)
in 2 rounds
-
Latest Funding Round
$6.68 M (USD), Series A
Jun 01, 2016
-
Investors
GO CAPITAL
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InFlectis BioScience
InFlectis BioScience offers a comprehensive portfolio of products and services, including Small Molecule Therapeutics.
Develops brain-penetrant molecules for treating neurological diseases
Funding Insights of InFlectis BioScience
InFlectis BioScience has successfully raised a total of $8.76M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $6.68 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InFlectis BioScience
InFlectis BioScience has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include GO CAPITAL, Remiges Ventures and Crédit Mutuel Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Remiges Ventures is engaged in biotech venture capital investments.
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
Growth and acquisition investments are managed by Credit Mutuel Equity.
|
Locked | Locked | Locked |
Investor details for InFlectis BioScience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InFlectis BioScience
Investment portfolio details for InFlectis BioScience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InFlectis BioScience
Detailed financials for InFlectis BioScience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inflectis Bioscience Comparisons
Peer comparison for InFlectis BioScience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InFlectis BioScience
InFlectis BioScience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for rare and orphan diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat rare genetic diseases
|
Detailed competitors of InFlectis BioScience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inflectis Bioscience
Complete news archive for InFlectis BioScience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InFlectis BioScience
InFlectis BioScience was founded in 2013 and raised its 1st funding round 2 years after it was founded.
InFlectis BioScience is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
Philippe GuEdat is the current CEO of InFlectis BioScience. They have also founded this company.
InFlectis BioScience is a funded company, having raised a total of $8.76M across 2 funding rounds to date.
InFlectis BioScience was founded in 2013 in Nantes, France, within the biotechnology sector. Small molecule drugs are developed to target cellular mechanisms against misfolded proteins, focusing on neurodegenerative and orphan diseases. Lead programs address Charcot-Marie-Tooth and Retinitis Pigmentosa. IFB-088 modulates the UbiquitinProteasome System via the PP1PPP1R15A interaction, while IFB-008 is advanced for related retinal and neurodegenerative conditions.
InFlectis BioScience's top competitors include Moderna, Spark Therapeutics and BridgeBio.
InFlectis BioScience offers Small Molecule Therapeutics.
InFlectis BioScience has 3 investors. Key investors include GO CAPITAL, Remiges Ventures, and Crédit Mutuel Equity.